US FDA approves breakthrough Alzheimer's drug | Robert Langreth & Kanoko Matsuyama / Bloomberg
Eisai Co.’s breakthrough Alzheimer’s disease drug Leqembi has gained full approval in the US. Yet, testing requirements and side effect warnings that may limit its use sent the company’s shares sliding. The Food and Drug Administration’s decision marks a milestone, as Leqembi is the first drug shown to slow progression…